All News

As the 41st Annual Miami Breast Cancer Conference approaches, Debu Tripathy, MD, prepares to step down as cochair.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.

A patient reported outcome analysis of the phase 3 OlympiA trial found that treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer ended.

Measurable residual disease–guided ibrutinib plus venetoclax in chronic lymphocytic leukemia appears to be particularly beneficial in patients with unmutated IGHV and specific genetic abnormalities.

The National Comprehensive Cancer Network has issued a category 2A recommendation for the use of goserelin for ovarian function suppression in those with breast cancer.

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.

Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.

Experts in multiple myeloma debated the use of teclistamab through an inpatient or outpatient setting.

A retrospective cohort study from the Trans-Atlantic Pancreatic Surgery Consortium determined a sustained OS rate with modified FOLFIRINIX in patients with pancreatic ductal adenocarcinoma.

Data from the phase 3 RATIONALE-315 study support the use of perioperative tislelizumab plus neoadjuvant chemotherapy in resectable stage II to IIIA non–small cell lung cancer.

Narjust Florez, MD, and Sandip P. Patel, MD, cohosted a X chat centering on treatment options for KRAS G12C non–small cell lung cancer.

Results from the phase 2 VISION trial have allowed for tepotinib to receive full approval by the FDA in non–small cell lung cancer harboring MET exon 14 skipping alterations.

Findings from a study raise concerns for the outcomes of individuals who experience an adverse financial event prior to a cancer diagnosis.

The FDA is expected to issue a Prescription Drug User Fee Act date for denileukin diftitox in cutaneous T-cell lymphoma within 30 days of accepting the biologics license application resubmission.

Investigators report clinical benefit with sacituzumab govitecan plus pembrolizumab across all prespecified patient subgroups with metastatic urothelial cancer in cohort 3 of the phase 2 TROPHY-U-01 trial.

Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.

The FDA set a Prescription Drug User Fee Act date of June 15, 2024 for repotrectinib as a treatment for those with advanced or metastatic solid tumors harboring an NTRK gene fusion.

Results from a phase 2 trial support the safety and tolerability of VGT-309 in patients with suspected lung cancer who undergo standard-of-care surgical resection.

Rachel Rau, MD, gives her perspective on the use of asparaginase treatments for pediatric patients with acute lymphocytic leukemia.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Julie M. Vose, MD, MBA, discussed the use of collaboration in driving progress in mantle cell lymphoma research and bridging the gap between research and clinical care.

Patients with metastatic pancreatic ductal adenocarcinoma may now receive irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.

Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.

Administering pegylated asparaginase continuously to pediatric patients with acute lymphoblastic leukemia appears to be safe without compromising the efficacy of treatment.

HEMO-CAR-T can now proceed with its evaluation as a treatment for those with acute myeloid leukemia as part of a phase 1 trial.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.